Recovery After Sugammadex(Propofol vs Sevoflurane) (Sugammadex2)
This study is currently recruiting participants.
Verified April 2012 by Hopital Foch
Sponsor:
Hopital Foch
Information provided by (Responsible Party):
Hopital Foch
ClinicalTrials.gov Identifier:
NCT01579851
First received: January 4, 2012
Last updated: April 17, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121018215655im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Sugammadex is used to reverse of a neuro-muscular block deep. It has been reported that its administration could induce signs of recovery despite continuation of anesthetic drugs. The goal of the present study is to look is the arte of this event is different according to the primary anesthetic agent used.
Condition | Intervention | Phase |
---|---|---|
Anesthesia |
Drug: Sugammadex |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Recovery After Sugammadex(TIVA Using Propofol vs Inhalation Anesthesia Using Sevoflurane) |
Resource links provided by NLM:
Further study details as provided by Hopital Foch:
Primary Outcome Measures:
- Number of patients with an increase in Bispectral Index after sugammadex injection [ Time Frame: One hour after anesthesia ] [ Designated as safety issue: No ]Increase in Bispectral Index (> 20) after sugammadex injection
- Number of patients with occurence of clinical signs of awakening after sugammadex injection [ Time Frame: One hour after anesthesia ] [ Designated as safety issue: No ]Clinical signs of awakening after sugammadex are wallowing, eye opening on demand, cough, spontaneous movements, response to simple commands, tearing, ...
Secondary Outcome Measures:
- T4/T1 ratio after sugammadex injection [ Time Frame: One hour after anesthesia ] [ Designated as safety issue: No ]Modification of T4/T1 ratio after sugammadex injection
- Number of patients with side effects due to sugammadex injection [ Time Frame: One hour after anesthesia ] [ Designated as safety issue: No ]Side effects after sugammadex injection are bradycardia, nausea or vomiting, pain, residual curarisation, awareness,...
Estimated Enrollment: | 70 |
Study Start Date: | January 2012 |
Estimated Study Completion Date: | January 2013 |
Estimated Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: Propofol-Remifentanil
Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
|
Drug: Sugammadex
sugammadex
|
Active Comparator: Sevoflurane-Remifentanil
Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
|
Drug: Sugammadex
sugammadex
|
![](https://webarchive.library.unt.edu/web/20121018215655im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- adult patients scheduled to receive general anesthesia with muscle relaxation achieved with rocuronium
Exclusion Criteria:
- Known drug allergy,
- Contra-indications to the use of propofol, remifentanil, rocuronium, sevoflurane, sugammadex
- Difficulty to use Bispectral Index monitor
- Inability to obtain a proper monitoring of muscle relaxation.
![](https://webarchive.library.unt.edu/web/20121018215655im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01579851
Contacts
Contact: Marc Fischler, MD | 4652442 ext 0331 | m.fischler@hopital-foch.org |
Locations
France | |
Hopital Foch | Recruiting |
Suresnes, Ile de France, France, 92151 | |
Contact: Morgan Le Guen, MD 46252442 ext 00331 m.leguen@hopital-foch.org | |
Principal Investigator: Morgan Le Guen, MD |
Sponsors and Collaborators
Hopital Foch
Investigators
Principal Investigator: | Morgan Le Guen, MD | Hopital Foch |
![](https://webarchive.library.unt.edu/web/20121018215655im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Hopital Foch |
ClinicalTrials.gov Identifier: | NCT01579851 History of Changes |
Other Study ID Numbers: | 2010/58 |
Study First Received: | January 4, 2012 |
Last Updated: | April 17, 2012 |
Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Additional relevant MeSH terms:
Propofol Remifentanil Sevoflurane Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Hypnotics and Sedatives Platelet Aggregation Inhibitors Hematologic Agents Anesthetics, Inhalation Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on October 17, 2012